MedTrace Logo

An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia

NCT01716221 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2016-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to document the clinical effects of bupropion and citalopram in a single subject with Friedreich Ataxia.

Conditions

  • Friedreich Ataxia

Interventions

DRUG

bupropion & Citalopram

DRUG

Bupropion & Placebo

DRUG

Placebo & Citalopram

DRUG

Placebo & Placebo

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Olga Klepitskaya, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01716221 on ClinicalTrials.gov